Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Bernstein Remains a Buy on Gilead Sciences (GILD)

Tipranks - Tipranks - Wed Apr 22, 7:38AM CDT

Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences today and set a price target of $160.00.

Claim 30% Off TipRanks

According to TipRanks, Breen is a 4-star analyst with an average return of 15.3% and an 81.25% success rate. Breen covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Moderna, and Merck & Company.

In addition to Bernstein, Gilead Sciences also received a Buy from Morgan Stanley’s Terence Flynn in a report issued on April 15. However, today, Barclays maintained a Hold rating on Gilead Sciences (NASDAQ: GILD).

See today’s best-performing stocks on TipRanks >>

Based on Gilead Sciences’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $7.93 billion and a net profit of $2.18 billion. In comparison, last year the company earned a revenue of $7.57 billion and had a net profit of $1.78 billion

Read More on GILD:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).